Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial

Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial

312002

Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial

The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a Phase 1b/2a clinical trial. Now, that dose and schedule will be tested, along with the standard oral combination treatment, in the trial’s second phase, the company said in a press release. “We are pleased to have concluded the first part of this trial, confirming the previous safety profile of tasquinimod in patients…

You must be logged in to read/download the full post.